The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maecker, H. T.
Right arrow Articles by Fisher, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maecker, H. T.
Right arrow Articles by Fisher, R. I.

The Journal of Immunology, Vol 149, Issue 5 1619-1625, Copyright © 1992 by American Association of Immunologists


ARTICLES

T cell receptor expression can switch on and off at a posttranslational level

HT Maecker, DM Jokinen and RI Fisher
Department of Biology, Loyola University of Chicago, IL 60626.

The human T acute lymphocytic leukemia cell line, SUP-T13, is a mosaic of TCR/CD3+ and TCR/CD3- cells. Individual SUP-T13 cells can spontaneously switch on and off surface TCR/CD3 expression. This switching was demonstrated by culturing and analysis of single cell clones that were TCR/CD3+ or TCR/CD3-. The rate of switching is about 10(-2)/cell per generation in either direction. This is too high to be due to a spontaneous mutation event. Furthermore, switched cells can revert at similar rates, as demonstrated by repeated cloning and reanalysis. This makes it likely that a regulatory change is responsible for switching. In support of this, all known TCR/CD3 proteins are found intracellularly in TCR/CD3- cells, and they associate with each other as in TCR/CD3+ cells. Furthermore, no structural abnormalities of the TCR/CD3 chains can be seen in TCR/CD3- cells using two-dimensional electrophoresis. However, in these cells, the chains accumulate in great excess intracellularly. This accumulation is specific to the TCR/CD3 complex, as other glycoproteins are still expressed normally on the cell surface. Thus, there is regulation of TCR expression at a posttranslational level. These TCR/CD3- cells may lead to the identification of novel protein(s) involved in glycosylating, processing, or transporting the TCR/CD3 complex. Potential loss of TCR/CD3 expression may also limit the feasibility of TCR-based therapies for T cell leukemias.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1992 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1992 by The American Association of Immunologists, Inc. All rights reserved.